Xencor, Inc.
Bispecific checkpoint inhibitor antibodies
Last updated:
Abstract:
The present invention is directed to heterodimeric anti-PD-1 x anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
Status:
Grant
Type:
Utility
Filling date:
7 Jun 2019
Issue date:
1 Feb 2022